Director Neal James R adds Processa (PCSA) shares in open trade

Rhea-AI Filing Summary

Processa Pharmaceuticals director Neal James R reported an open-market purchase of the company’s Common Stock. On March 31, 2026, he bought 789 shares at a price of $2.535 per share, bringing his direct ownership to 818 shares after the transaction, indicating a small, routine insider buy.

Insider Trade Summary

Net Buyer: 789 shares ($2,000)

Net Buy 1 txn

Insider Neal James R

Role Director

Bought 789 shs ($2K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	789	$2.535	$2K

Holdings After Transaction: Common Stock — 818 shares (Direct)

Footnotes (1)

Key Figures

Shares purchased: 789 shares Purchase price: $2.535 per share Shares owned after: 818 shares

3 metrics

Shares purchased 789 shares Open-market purchase on March 31, 2026

Purchase price $2.535 per share Price paid for Common Stock in the transaction

Shares owned after 818 shares Total direct holdings following the reported trade

Key Terms

open-market purchase, Common Stock, Form 4

3 terms

open-market purchase financial

"transaction_action: "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Neal James R

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH CALIFORNIA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/31/2026		P		789	A	$2.535	818	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ James Neal by John J. Wolfel, as Attorney-in-Fact	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider trade did Processa Pharmaceuticals (PCSA) director Neal James R report?

Director Neal James R reported buying 789 shares of Processa Pharmaceuticals Common Stock. The open-market purchase occurred on March 31, 2026 at $2.535 per share, increasing his direct holdings to 818 shares after the transaction as disclosed in the Form 4 filing.

At what price did Neal James R buy PCSA shares in the reported transaction?

Neal James R purchased Processa Pharmaceuticals Common Stock at $2.535 per share. The Form 4 shows an open-market transaction for 789 shares on March 31, 2026, reflecting a relatively small-scale insider purchase at that disclosed per-share price.

How many Processa Pharmaceuticals (PCSA) shares does Neal James R now hold?

Following the reported purchase, Neal James R directly holds 818 shares of Processa Pharmaceuticals Common Stock. This total reflects the addition of 789 shares acquired in the March 31, 2026 open-market transaction, as detailed in the Form 4 insider filing data.

Was the Neal James R PCSA stock transaction a buy or a sell?

The transaction was a buy. The Form 4 identifies it as an open-market purchase of 789 shares of Processa Pharmaceuticals Common Stock on March 31, 2026, with the transaction direction labeled as a net-buy in the summarized insider activity data.

How large is Neal James R’s recent PCSA purchase compared with his disclosed holdings?

The reported transaction added 789 shares, resulting in total direct holdings of 818 shares. This indicates the purchase meaningfully increased his stake in share-count terms, though the absolute size of the position remains small based on the figures disclosed in the Form 4.